Clinical trials: Flavivirus Infections
Japanese Encephalitis, Chickenpox
Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine
The purpose of this study is to observe the occurrence of adverse events and seroconversion rate, geometric mean titres (GMTs) of live attenuated varicella vaccine，live attenuated JE vaccine and live attenuated varicella vaccine…
- Trial name
- NCT01815073
- Testing
- Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine, Live Attenuated Varicella Vaccine, live attenuated JE vaccine
- Where
- China
- Volunteers
- 497 people, healthy volunteers welcome
- Sponsor
- Changchun Keygen Biological Products Co., Ltd.
Dengue
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a…
- Trial name
- NCT05048875
- Testing
- Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults
This study is being conducted to evaluate the safety and immunogenicity and antibody persistence of the candidate dengue vaccine.
- Trial name
- NCT02421367
- Where
- 2 sites in United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Zika Virus Infection
Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA
The purpose of this study is to evaluate the performance of the ZIKV Detect™ 2.0 IgM Capture ELISA using archived confirmed ZIKV positive and confirmed ZIKV negative human serum samples.
- Trial name
- NCT03776903
- Testing
- ZIKV Detect™ 2.0 IgM Capture ELISA
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- InBios International, Inc.
Dengue Virus, Dengue Fever
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
The aim of the trial was to evaluate the use of a tetravalent vaccine, CYD dengue vaccine, against dengue disease. Primary Objectives: To describe the humoral immune response to dengue before and after each vaccination with…
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00788151
- Testing
- CYD Dengue Vaccine Serotypes 1, 2, 3, and 4, Pneumococcal polysaccharide vaccine
- Where
- Peru
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Yellow Fever
Immunogenicity of Yellow Fever Vaccine in a Pediatric Population Vaccinated at 12-23 Months of Age in Argentina
Northern Argentina is a risk area for yellow fever (YF). Recent studies have suggested that immunity wanes in children vaccinated between 9 and 23 months of age.
- Trial name
- NCT05644145
- Testing
- Serological study after yellow fever vaccination
- Where
- 3 sites in Argentina
- Volunteers
- 361 people, healthy volunteers welcome
- Sponsor
- Ministry of Public Health, Argentina
Dengue, Zika
Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities
Arboviral diseases such as dengue, Zika, and chikungunya, transmitted by Aedes mosquitoes, remain an important public health concern in Colombian communities.
- Conditions
- Dengue, Zika, Chikungunya, Aedes-borne Diseases
- Trial name
- DigiAedes (NCT07517731)
- Testing
- Full intervention, Partial intervention
- Where
- 2 sites in Colombia, Germany
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of Freiburg
Dengue
Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults
This descriptive study will evaluate the safety and immunogenicity of 3 different formulations of the WRAIR dengue vaccine compared to a placebo.
- Trial name
- NCT00350337
- Testing
- Pre-transfection F17, Post-transfection F17, Post-transfection F19
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Tick-borne Encephalitis
Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination
The phenomenon of no- and low-responsiveness has been described after applications of different vaccines (e.g. hepatitis B, TBE) and is concerning about 2-10% of the vaccinees.
- Trial name
- NCT00804219
- Testing
- TBE vaccination and influenza vaccination
- Where
- Austria
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Encephalitis, Tick-borne
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
The aim of this study is to evaluate the safety of the third vaccination with FSME-IMMUN NEW in all volunteers who received both vaccinations in Baxter study 208 (safety study of FSME IMMUN NEW and ENCEPUR in healthy volunteers…
- Trial name
- NCT00161876
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 8 sites in Poland
- Volunteers
- 3,973 people, healthy volunteers welcome
- Sponsor
- Pfizer
Dengue
Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter
AIMS \& OBJECTIVES To evaluate the effectiveness of administering of Carica folia mother tincture to healthy individual's Platelet count.
- Trial name
- CF2013 (NCT02016027)
- Testing
- Carica folia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fr Muller Homoeopathic Medical College
Dengue, Arbovirus Infections
Improving Disease Prevention Strategies by Integrating Socio-spatial Characterization of Human Mobility
In contrast to the trend expected based on existing prediction models, dengue incidence was historically low during the pandemic mobility restrictions of 2020-2021 in most dengue endemic countries.
- Conditions
- Dengue, Arbovirus Infections, Epidemic Disease, Behavior, Health
- Trial name
- DI-MOB (NCT06599970)
- Testing
- No intervention
- Where
- Cuba
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Japanese Encephalitis, Varicella
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
The aim of the study is to investigate the memory immune response and the yearly persistence of the immunity against Japanese Encephalitis (JE) after vaccination with Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in…
- Trial name
- NCT01190228
- Testing
- JE-CV Vaccine, Varicella Vaccine
- Where
- Philippines
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis Virus Disease
Purified Inactivated Japanese Encephalitis Vaccine
This study evaluates the immunogenicity and safety of a purified inactivated JE vaccine compared to a commercialized JE vaccine.
- Trial name
- NCT04223037
- Testing
- Japanese Encephalitis Vaccine produced by IMBCAMS, Japanese Encephalitis Vaccine produced by Liaoning Chenda
- Where
- China
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Zika Virus
Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
This is a phase 1 double-blind, placebo controlled trial designed to evaluate the safety, reactogenicity, and immunogenicity of a single dose of the live attenuated Zika vaccine rZIKV/D4Δ30-713 in adults with no history of…
- Trial name
- NCT03611946
- Testing
- Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml), Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Japanese Encephalitis, Measles
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
This is a phase IV, randomized, controlled, open-label study proceed in healthy children aged 8 months in China. The primary objective is to demonstrate the immunogenicity of simultaneous administration of JEV-I and MMR is not…
- Conditions
- Japanese Encephalitis, Measles, Mumps, Rubella
- Trial name
- NCT06331702
- Testing
- Vero cell-drived inactive Japanese encephalitis vaccine, Measles-Mumps-Rubella Vaccine
- Where
- China
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Prevention of Zika Infection, Zika-Specific Immune Response
VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults
Background: People get Zika virus from infected mosquitos. They usually don t get very sick. But birth defects were reported in babies born to mothers who had Zika infection.
- Trial name
- NCT02996461
- Testing
- VRC-ZKADNA090-00-VP
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease
This is a phase 1 study to evaluate the safety of a vaccine (DENV-1 PIV) for the prevention of dengue fever.
- Trial name
- DENV-1 PIV (NCT01502735)
- Testing
- DENV-1 PIV, 2.5 µg, DENV-1 PIV, 5 µg
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Japanese Encephalitis
Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country
This is a randomized, open-label Phase 3 study including children aged >9 months to <17 years and 7 months who have been vaccinated with IXIARO in study IC51-323.
- Trial name
- NCT01296360
- Testing
- IXIARO
- Where
- 3 sites in Philippines
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Tick-Borne Encephalitis
Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac
Many viral infections of global importance, including HIV, are transmitted across the mucosal surface of the genital tract. As immunity against these infections is likely to be primarily mediated by antibodies in mucosal…
- Trial name
- CRC306 (NCT01710189)
- Testing
- TicoVac
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Surrey